Literature DB >> 30579900

Proteomic analysis of iron-regulated membrane proteins identify FhuE receptor as a target to inhibit siderophore-mediated iron acquisition in Acinetobacter baumannii.

Vishvanath Tiwari1, Moganty R Rajeswari2, Monalisa Tiwari3.   

Abstract

Survival of the Acinetobacter baumannii inside host requires different micronutrients such as iron, but their bioavailability is limited because of nutritional immunity created by host. A. baumannii has to develop mechanisms to acquire nutrient iron during infection. The present study is an attempt to identify membrane proteins involved in iron sequestration mechanism of A. baumannii using two-dimensional electrophoresis and LC-MS/MS analysis. The identified iron-regulated membrane protein (IRMP) of A. baumannii was used for its interaction studies with different siderophores, and designing of the inhibitor against A. baumannii targeting this IRMP. Membrane proteomic results identified over-expression of four membrane proteins (Fhu-E receptor, ferric-acinetobactin receptor, ferrienterochelin receptor, and ferric siderophore receptor) under iron-limited condition. A. baumannii produces siderophores that have good interaction with the FhuE receptor. Result also showed that FhuE receptor has interaction with siderophores produced by other bacteria. Interaction of FhuE receptor and siderophores helps in iron sequestration and survival of Acinetobacter under nutritional immunity imposed by the host. Hence it becomes essential to find a potential inhibitor for the FhuE receptor that can inhibit the survival of A. baumannii in the host. In-silico screening, and molecular mechanics studies identified ZINC03794794 and ZINC01530652 as a likely lead to design inhibitor against the FhuE receptor of A. baumannii. The designed inhibitor is experimentally validated for its antibacterial activity on the A. baumannii. Therefore, designed inhibitor interferes with the iron acquisition mechanism of Acinetobacter hence may prove useful for preventing infection caused by A. baumannii by limiting nutrient availability.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Carbapenem resistance; FhuE receptor; Inhibitor designing; Iron-Regulated Membrane Protein (IRMP); Siderophores

Mesh:

Substances:

Year:  2018        PMID: 30579900     DOI: 10.1016/j.ijbiomac.2018.12.173

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  6 in total

1.  Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.

Authors:  Vishvanath Tiwari
Journal:  Int J Biol Macromol       Date:  2021-01-07       Impact factor: 6.953

2.  CRISPR-Cas in Acinetobacter baumannii Contributes to Antibiotic Susceptibility by Targeting Endogenous AbaI.

Authors:  Yuhang Wang; Jie Yang; Xiaoli Sun; Mengying Li; Pengyu Zhang; Zhongtian Zhu; Hongmei Jiao; Tingting Guo; Guocai Li
Journal:  Microbiol Spectr       Date:  2022-08-08

3.  Molecular mechanism of antimicrobial activity of chlorhexidine against carbapenem-resistant Acinetobacter baumannii.

Authors:  Deepika Biswas; Monalisa Tiwari; Vishvanath Tiwari
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

4.  Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis.

Authors:  Vishvanath Tiwari
Journal:  Heliyon       Date:  2020-09-30

5.  Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport.

Authors:  Casin Le; Camila Pimentel; Fernando Pasteran; Marisel R Tuttobene; Tomás Subils; Jenny Escalante; Brent Nishimura; Susana Arriaga; Aimee Carranza; Vyanka Mezcord; Alejandro J Vila; Alejandra Corso; Luis A Actis; Marcelo E Tolmasky; Robert A Bonomo; Maria Soledad Ramírez
Journal:  Biomedicines       Date:  2022-03-03

6.  De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2.

Authors:  Vishvanath Tiwari
Journal:  Biol Open       Date:  2020-10-15       Impact factor: 2.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.